Please assess the completion status of the following clinical trial:

Trial Title: Therapy to Prevent Sexual Pain in Breast Cancer Survivors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Eligibility Criteria~1. Women aged 18 to 70 years old.~2. Has a previous diagnosis of breast cancer (ductal or lobular carcinoma, invasive).~3. 1 year from diagnosis of breast cancer.~4. Stable heterosexual partnership =/\>5 years or by investigator discretion.~5. More than 6 months of consistent insertional pain with intercourse (may have stopped having intercourse due to this consistent experience of pain).~6. Menopausal, demonstrated by at least one of the following:~   i. cessation of menses for 1 years ii. Bilateral oophorectomy iii. Follicle Stimulating Hormone (FSH) level \>25 in women below age 50 with an ovary and scarred or absent uterus (acceptable FSH levels can be inferred if the woman's oncologist monitors FSH during aromatase inhibitor therapy).~7. Willingness to enter a study comparing a topical placebo liquid to topical liquid lidocaine.~8. Willingness to evaluate the liquids by use of a tampon test as many as 4 times per month, and willingness to attempt intercourse if the tampon test indicates tolerable penetrative pain.~3.2 Exclusion Criteria~1. Diagnosis of benign or malignant phyllodes tumor of the breast.~2. Consistently has pain in the pelvis or low abdomen during or after intercourse (deep dyspareunia).~3. Has developed shrinkage of the vaginal opening or vaginal length to the point of being too small to succeed in having vaginal penetration with the partner (will also be assessed at the clinical exam).~4. Partner has a problem of sexual dysfunction limiting his performance or making it inconsistent.~5. The potential subject or her partner has a serious current medical condition that might interrupt completion of a 6 month study.~6. Potential subject has been diagnosed by a physical therapist with significant pelvic floor muscle dysfunction causing pain (pelvic floor myalgia).~7. Potential subject has used topical or systemic estrogen within the last 4 months.~8. Has continued tenderness of vestibule mucosa immediately after application of both test liquids.~9. Allergy to lidocaine or other numbing agents.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Topical liquid lidocaine (Type: ACTIVE_COMPARATOR): None
- Topical Saline (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).